• Accurate, powerful vision, mission and value statements can distinguish companies from their competition
• The inability to agree upon, articulate these key elements can cause serious problems for a company
• Adherence to guiding principles and values serves all in arriving at the most effective and collaborative decisions, notes SHRG

Aligning a company’s vision, mission and values with its culture seems like an obvious thing, but it’s not unusual to have a disconnect between the two, reports a recent Direct Selling News (DSN) article (https://ibn.fm/GQkuj). Yet companies with powerful, accurate vision, mission and value statements, such as Sharing Services Global (OTCQB: SHRG), often distinguish themselves from others operating in the same space.

“Who are you? It sounds like a silly question. Or the beginning of an awkward introduction,” writes Paul Adams, author of the DSN article. “When I ask the question to a group of executives, I’m asking about who they are as a company. What do you stand for? How do you act? What expectations do you have for each other and the team around you? But, the answers I get are—normally—about the products, the opportunity or the way you want people in the field to think of the company.”

The inability to articulate vision (the company’s big goal), mission (how the company will achieve the vision) and values (what a company cherishes and how it treats people) can cause serious problems, writes Adams. He has been involved in the direct-selling channel for more than three decades and has helped hundreds of companies invent, reinvent and solidify their messaging, strategy and execution.

Time spent clearly identifying these key elements of a business cannot be underestimated. “Think of the vision, mission and values as the guardrails for your business,” Adams suggests. “If you know what matters most and what is nonnegotiable, you can easily say no to ideas that don’t fit. More importantly, you can say yes and run faster inside the lane you’ve created for yourself when everyone knows what matters most.”

Clear vision, mission and values have guided Sharing Services Global in its commitment to promote health, wealth and happiness by reshaping how entrepreneurs succeed today. Recognizing what Adams teaches (https://ibn.fm/mRkEm), the company notes that “the quality of internal decisions determines the quality and success of outcomes. Emotion decision making can often tilt the decision-making objectives. Adherence to guiding principles and values serve all in arriving at the most effective and collaborative decision.”

The company states its guiding principles and values as follows:

• We exist to serve people
• Technology must always be a strength
• Less is more
• Research is the foundation to excellence in decision making
• Quality is the foundation to sustainable success
• Speed is important
• No compromise

Sharing Services doesn’t just talk the talk of values and principles; the company is adamant about transforming these statements into real-world and real-life action as it works to capture profitable market share through acquisition, new business entry and management of diverse business models. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force.

For more information, visit the company’s websites at www.SHRGInc.com, www.TheHappyCo.com and www.ShareHapiTravel.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• President Biden issued a pardon for federally incarcerated inmates with minor marijuana possession charges, urging governors to do the same at the state level
• The President also requested a reclassification of cannabis, as it is currently listed above other drugs which are key factors in the overdose epidemic
• Flora Growth, through its Colombian cultivation, is producing a higher quality product at lower-than-average cost margins due to the country’s stance on cannabis regulations

With midterm elections right around the corner, voters in five states – Arkansas, Maryland, Missouri, North Dakota, and South Dakota – will determine the legality of recreational marijuana use within each state on voting day. If passed, these states will join 19 states, two territories, and D.C., which have embraced recreational marijuana use legalization. Currently, 37 states, three territories, and D.C. already recognize the legal use of cannabis for medicinal reasons. According to Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws, “When you look at ballot campaigns in the past, you’ll see that this is an issue that crosses traditional party lines. We anticipate similar outcomes this November” (https://ibn.fm/9BJbc).

Early in October, President Biden released a formal statement on his goals for marijuana reform across the country. Citing how criminal records can impose unnecessary barriers to employment, housing, and educational opportunities – more disproportionately to those people of color who are more often arrested, prosecuted, and convicted. His announcement included three steps – pardoning all prior federal offenses of simple marijuana possession, urging the governors to do the same in their respective states, and initiating a review by the Secretary of Health and Human Services and the Attorney General to review the classification of marijuana, which is classified higher than drugs currently driving the overdose epidemic (https://ibn.fm/J9zGk).

President Biden’s request for the reclassification of marijuana and the pardons issued at the federal level is helping to change the landscape of the cannabis industry. An international cannabis company, Flora Growth (NASDAQ: FLGC), is focused on cannabis brand building, leveraging natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. The company operates one of the largest outdoor cultivation facilities in the world with the aim of marketing higher-quality premium products at below-market prices. Flora Growth offers low-cost cannabis cultivation, an expansive brand and product portfolio, and a strategic global distribution platform. The NASDAQ listing of the company precludes it from participating in the US domestic market for adult use presently due to federal prohibitions.

The global cannabis cultivation market was valued at $323.9 billion in 2022. The market is expected to grow at a CAGR of 21.4% from 2022 to 2030, resulting in a market valuation of $1,844.1 billion by 2030. The growing interest in legalizing cannabis for medicinal and recreational use is a driving factor in the market’s growth (https://ibn.fm/oeLUe). Liberalization of laws regarding cannabis cultivation, especially hemp cultivation, has created opportunities in the market – which Flora Growth is leveraging, with the cultivation of its product at a key Colombian farm for international markets.

Flora Growth’s Colombian cultivation provides key advantages, including location, climate, and natural resources – all of which reduce the costs of traditional cultivation. With Colombia’s administration focused on progressive cannabis regulations, Flora Growth can produce high-quality, high-margin products leveraging Colombia’s geo-advantageous location. Over 70% of all cut flowers imported into the US come from Colombia – but Flora Growth is taking it one step further by reducing the associated costs, coming in at just $.06 per gram.

For more information, visit the company’s website at www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

Medical experts from all over the globe are invited to attend the 3rd Human Factors Engineering & Usability Studies Congress, a live-streaming event that will help medical device professionals adapt to regulatory challenges, logistics, and scheduling issues in a remote work environment.

The event is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing b2b events. The global event company caters to the informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries.

The conference will commence with an opening speech from Joseph Purpura, Associate VP, Executive Director, and Head of Medical Device Safety, ABBVIE / ALLERGAN AESTHETICS.

Sessions will cover best practices of data access while still maintaining the patient’s privacy – a key topic for providing device designers with insights into patient preferences that are pivotal in designing better and more efficient user experiences for future uses. Panel discussions will explore common dilemmas on subjective observations. Attendees can learn ways of identifying errors and pre-error steps.

The experts will go beyond the mechanical error to understand the users’ perceptions and emotions. And by popular audience demand, the conference will also provide an in-depth understanding of usability concerns around surgical robots. These are complex systems with multiple layered user interfaces. Experts will talk about the steps that must be taken to keep these surgical robots manageable and test them to meet timelines.

Professionals and executives will also learn how much realism is adequate in simulated user environments. They will also understand that a well-executed summative test requires input from many disciplines, including risk management, product management, quality assurance, device development, training, and others.

Industry leaders with also discuss the importance of human factors and how HF engineers can act as a differentiator among competitors, gain a deeper understanding of end-users, design more customer-centric products, and ultimately save on costs.

To learn more, please visit https://ibn.fm/uxij8.

• IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia
• As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC based formulation on Alzheimer’s patients
• The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines
• Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S.

India Globalization Capital (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (“THC”) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (“NPS”) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (“CBD”)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (“PMS”) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (“IP”) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

For more information, visit the company’s website at https://igcinc.us/.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

• Lexaria, through its patented DehydraTECH(TM) technology, is improving the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, thereby achieving an improved speed of onset, and brain absorption of APIs
• Hypertension currently affects nearly 50% of all American adults, with the American Heart Association describing it as a “silent killer”, and is now being studied for its effects during pregnancy
• The company has received positive feedback for its pre-Investigational New Drug meeting from the FDA and has reported that it remains on track to file its full IND application by late 2022/early 2023
• It looks to capitalize on the growth of the antihypertension market, which is set to hit $40 billion by 2031, up from $30.2 billion in 2021

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has been on an aggressive push to perfect its potential hypertension treatment, building on its patented DehydraTECH(TM) technology. Through improving the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, Lexaria can achieve an improved speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”), which is integral to the overall treatment of conditions including but not limited to hypertension. The American Heart Association (“AHA”) has described hypertension or high blood pressure as a “silent killer,” with nearly 50% of American adults having the condition (https://ibn.fm/47O9g). In addition, hypertension during pregnancy comes with severe short-term risks for both mothers and their offspring, although treating the condition among these individuals is still being studied. A recent Chronic Hypertension And Pregnancy (“CHAP”) study by Tita and colleagues sought to offer more insights into hypertension treatment during pregnancy. With over 2400 participants involved, the group noted that supporting treatment of mild chronic hypertension in pregnancy improved pregnancy outcomes. According to the study’s results, this was primarily due to a reduction in preeclampsia with severe features in medically indicated preterm birth (https://ibn.fm/erg5g). Typically, the risks associated with hypertension in pregnancy include stroke, pulmonary oedema, acute kidney injury, preeclampsia and eclampsia, placental abruption, or even death. To the offspring, the effects can include preterm birth, birth at small-for-gestational age, or even perinatal death (https://ibn.fm/AENiV). With such risks, there is a need for effective hypertension treatments during pregnancy. Lexaria is looking to meet that demand. Through its DehydraTECH technology, Lexaria is looking to meet the serious unmet need in the antihypertension medication market in general and during pregnancy. It aims to achieve this by directly pushing for its products and technology and licensing it for delivering fat-soluble active molecules and drugs to strategic partners worldwide. Lexaria is also looking to capitalize on the growth of the antihypertension drugs market, which is set to hit $40 billion by 2031, up from $30.2 billion in 2021 (https://ibn.fm/ExXfU). It also hopes to carve out a significant market share globally and in the United States. Lexaria’s management is optimistic about the company’s current trajectory. It is confident that with time, its DehydraTECH-CBD for the treatment of hypertension will receive approval from the United States Food and Drug Administration (“FDA”). The company has so far received positive feedback from its pre-Investigational New Drug meeting (“IND”). John Docherty, Lexaria’s President, has even expressed the company’s delight, citing how helpful this feedback will be in compiling and filing its IND application. As a result, Lexaria remains on track to file its full IND application with the FDA by late 2022/early 2023, as previously announced (https://ibn.fm/joqTn). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Mullen’s U.S. test drive tour added additional dates, locations based on overwhelming response
• Tour provides hands-on opportunity to see the Mullen FIVE
• Second leg of tour, which will feature the Mullen FIVE RS, already in the planning stage

Mullen Automotive (NASDAQ: MULN) is ending the year with a bang with its Mullen FIVE “Strikingly Different” U.S. Test Drive Tour (https://ibn.fm/eDWyL). The tour, which features the company’s innovative Mullen FIVE, kicked off in October. With additional locations added based on demand, the tour now has eight stops scheduled throughout November and December. “When we announced the [first] location, we received an overwhelmingly positive response and were completely booked out in a matter of hours,” said Mullen CEO and chair David Michery. “So, we decided to add an additional LA-area stop to ensure more people have the opportunity to experience the FIVE. It’s been a remarkable journey for us to get to this point of officially starting the Mullen FIVE demonstrator U.S. tour. We’re beyond grateful for the incredible support we’ve received so far.” The tour is designed to provide potential buyers and other interested parties with a hands-on opportunity to see the Mullen FIVE, including a up-close-and-personal look at PERSONA, MLN’s proprietary personal vehicle assistant (“PVA”) and its proprietary infotainment technology. According to the company, PERSONA uses facial recognition technology to offer an unparalleled, customized driving experience. In addition, the tour is designed to gather invaluable feedback as Mullen will interview consumers to gain insights into customer needs and suggested improvements. The tour showcases the first fully functional demonstrator Mullen FIVE vehicles, which were developed jointly by Mullen and hofer powertrain. The FIVE EV Crossover vehicles feature a 120-kWh battery pack, 325 miles of range, 0 to 60 mph in 3.2 seconds and a top speed of 155 mph. “We are thrilled to launch the first fully functional, demonstrator FIVE EV Crossover vehicles this October,” said Michery. “Mullen and hofer have been working diligently to have these vehicles ready in time for Mullen’s ‘Strikingly Different’ U.S. tour. Congratulations to both the hofer and Mullen teams on being able to make this monumental effort a reality.” The national tour includes stops in California, Nevada and Texas in November; December locations include Tennessee, Florida, Georgia and North Carolina. Reservations are requested, and Front Row FIVE reservation holders will be offered the first chance to actually test drive the Mullen FIVE. Interested individuals can reserve their spots at the “Strikingly Different” test drive tour here. Mullen is already planning a second leg of the “Strikingly Different” Tour with a focus on the East Coast, Midwest and Northwest, with some California stops as well. Slated for spring 2023, the tour will spotlight the Mullen FIVE RS, which is a high-performance EV sport crossover featuring 1,100 horsepower, a top speed of 200 mph and acceleration from 0 to 60 mph in only 1.9 seconds. Mullen is a Southern California–based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. For more information about the company, visit www.MullenUSA.com. NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

• Correlate Infrastructure Partners Inc. is a company that helps commercial real estate industry clients make the transition to climate-friendly energy sources in highly affordable ways
• Climate friendliness has increasingly occupied the attention of international governments amid reports of growing extreme weather events and forecasts for devastating impacts on global human lifestyles as well as on other living creatures
• International agreement on climate-friendly energy use transitions in 2015 has established a framework for goals, but experts fear the goals aren’t being met
• Despite a slow response to climate change goals, a Bloomberg analysis notes growing optimism for renewable energy adoption as dozens of nations continue to increase their momentum in making the transition away from carbon pollutants

Extreme weather events and drastic drops in resources for select industries continually generate news reports about climate change impacts on humanity globally. The United Nations-sponsored Paris accords of 2015 drew international cooperation in reducing carbon-based pollutants to target levels by the year 2030, but a recent statement by the UN’s climate experts noted that governments around the world still are “nowhere near” the level of change necessary for achieving the Paris 2015 goal (https://ibn.fm/McjS8). Despite the worried outlook of those experts, Bloomberg reports more optimistically that 87 countries are making great strides in momentum for transitioning to green energy — drawing at least 5 percent of their electricity from wind and solar power and trending in an upward direction (https://ibn.fm/kbLyc). “The US hit 5% in 2011 and surged past 20% renewable electricity last year,” the analysis states. “If the country follows the trend set by others at the leading edge, wind and solar will account for half of US power-generating capacity just 10 years from now. That would be years—or even decades—earlier than major forecasts.” Clean energy solutions innovator Correlate Infrastructure Partners (OTCQB: CIPI) is a company working to facilitate the expansion of renewable electricity use in the United States. Correlate Infrastructure — CIPI — empowers the commercial real estate industry (companies that develop and rent out commercial building properties) to reform their energy use strategies and find cost-effective solutions for turning a dream into action. CIPI’s efforts help propel the United States toward its eventual goal for green technologies that are affordable at mass adoption levels. “With all good technologies, there comes a time when buying the old tech no longer makes sense. Think smartphones in the 21st century, color TVs in the 1970s, or even gasoline-powered cars in Henry Ford’s day,” the Bloomberg report states. “Sales move at a crawl in the early-adopter phase, then surprisingly quickly once things go mainstream. … Once the tough investments in manufacturing have been made and consumer preferences start to shift, the first wave of adoption sets the conditions to go much bigger.” CIPI’s subsidiaries work in harmony to help clients analyze their utilities usage, anticipate improvements they can make to their energy-use operations, and anchor financing opportunities as capital assets. The recently codified Inflation Reduction Act (“IRA”), in particular, establishes federal funding opportunities in support of renewable energy adoption. Amid economic uncertainties spawned by the COVID pandemic and Russia’s war against Ukraine, underscored by rising consumer prices and fears of a potential future slide into economic recession, the IRA appears to offer a stable promise of climate consequence. “Even if the United States slips into recession in the next year, … the IRA’s programs and incentives will keep flowing no matter the macro environment, which makes betting on clean energy one of the most certain economic trends of the next few years,” a recent Atlantic commentary on green energy adoption states (https://ibn.fm/xryH4). “Clean energy is now the safe, smart, government-backed bet for conservative investors.” For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• An overwhelming majority of surveyed entrepreneurs (74.8%) reported being somewhat or very happy
• Guidant Financial report describes entrepreneurs as “backbone of the COVID recovery”
• SHRG and its Happy Company have been part of that wave of entrepreneurial growth

Small business owners tend to be happier, according to a recent Guidant Financial 2022 trends report (https://ibn.fm/jrhWW). The report just reaffirms what Sharing Services Global (OTCQB: SHRG) already knew when it rebranded its direct-sales division as The Happy Company early last year. “Entrepreneurs are just happier, according to Guidant Financial’s 2022 Small Business Trends report,” states a Direct Selling News article. “The past two years and counting have been inordinately challenging for small business owners, but even amid these struggles, an overwhelming majority of these entrepreneurs (74.8%) reported being somewhat or very happy. When Guidant Financial compared these numbers to other happiness scales, the results portray business owners as happier than the average American.” The article notes that while these entrepreneurs obviously face challenges as they work to maintain and even grow their businesses, Guidant Financial described them as “the backbone of the COVID recovery.” Sharing Services and its Happy Company have been part of that wave of entrepreneurial growth. SHRG announced the rebranding of its direct-sales division in March 2021, noting that the newly titled brand had received a $30 million investment increase from its largest shareholder, Document Security Systems. In addition, SHRG plans to launch a travel company to add to its direct-selling arsenal, focusing on providing exclusive benefits and first-class discount travel opportunities to its brand partners and customers (https://ibn.fm/sxwlE). “We will be in the right place at the right time on our launch of Hapi Travel Destinations,” said SHRG CEO John “JT” Thatch (https://ibn.fm/mQ7ko). “All the pieces for a successful launch are falling into place as consumers are starting to re-engage with travel, hospitality and vacations on a regular basis.” Thatch added, “I am a firm believer that a travel experience with friends and family is one of the most meaningful things you can provide your family. Our hope is that this turnkey travel solution we’ve created will open up travel opportunities for so many consumers who were previously only able to dream about grand adventures.” Sharing Services Global Corporation is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit www.SHRGInc.com, www.TheHappyCo.com, and www.HapiTravel.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Flora Growth recently participated in an earnings call in which the management team discussed the company’s financials as well as its growth strategy and outlook for the remainder of fiscal 2022 as well as 2023
• The company noted it had exited a period of investment and is now focusing on execution
• The period of investment saw the company acquire synergistic brands that, collectively, create a direct-to-consumer house of brands, enabling the company to enter nearly any target market regardless of the legal status of cannabis
• The company also invested in the infrastructure necessary for the activation of its cultivation facility in Colombia, enabling it to progressively capitalize on new market opportunities that accompanied the legalization of the export of cannabis flower

The start of the second half of fiscal 2022 on July 1 marked an important transition point for Flora Growth (NASDAQ: FLGC), an internationally focused cannabis brand builder on a mission to build a design-led collective of plant-based wellness and lifestyle brands. The company, which had previously focused on expansion driven by acquisitions and other forms of capital-intensive investments, had now entered a period of execution, as CFO Elshad Garayev and CEO Luis Merchan separately emphasized in their presentations during the company’s H1 2022 earnings call held August 15 (https://ibn.fm/yaUQo). This ongoing execution phase rests on a solid foundation built on a bed of strategic investment strategies that were markedly different from industry peers, according to Jason Warnock, Flora Growth Chief Commercial Officer. The initial thinking by a majority of companies entering a new cannabis market, Warnock says, often involves a rush to build infrastructure and allocate capital toward constructing massive facilities in anticipation of regulatory changes that may breathe life into these investments. Unfortunately, this gamble sometimes proves unrewarding as the changes do not always materialize. On its part, however, Flora Growth took a different approach that entailed building, through acquisitions, and activating a brand portfolio that includes JustCBD, Vessel Brands Inc., Masaya, No Hemp Co, and Mambe. The resulting house of brands has enabled the company to operate legally in the United States despite the federal illegality of cannabis and the company’s NASDAQ listing, which precludes it from participating in the US domestic market. Additionally, it has ensured Flora Growth does not lock its capital expenditure (“CapEx”) in infrastructure that does not yield returns in the short or long term. Moreover, and by integrating each brand into its operations, Flora Growth has created a collective capable of capitalizing on emerging opportunities in different parts of the world. This has, in turn, allowed the company to expand its global reach while navigating the different regulatory environments in the different target markets, as Flora Growth Chief Marketing Officer Jessie Casner explained in her presentation. “Flora Growth’s House of Brands enables the company to enter nearly any target market regardless of the legal status of cannabis or its derivatives because of the diversity of its product offerings. This means Flora can begin to build a customer base, distribution networks, and supply chains in these regions in advance of movements on cannabis regulations affording us a revenue-generating infrastructure that positions us for the future,” said Casner. But the House of Brands is just one pillar of the company’s growth strategy. The other, its commercial operation, includes a cultivation facility located on a 247-acre property in Bucaramanga, Colombia, and Flora Labs, the company’s manufacturing and R&D centers, located in Bogota and Bucaramanga, Colombia and Fort Lauderdale, Florida, that produce pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. (The company also has a life sciences division that constitutes its third growth pillar.) On April 1, following the passing of Resolution 539, which authorizes the export of cannabis flower from Colombia (https://ibn.fm/g9r26), Flora Growth commenced the full activation of its cultivation facility. Specifically, the company began cultivating different strains of the cannabis plant for export, departing from its previous focus on the cultivation of cannabis for use in the development of derivative products. According to the earnings call, the company has so far cultivated 8 hectares, five of which support high THC strains of cannabis while the rest support high CBD strains of the plant. “We continue to invest in the necessary infrastructure of our cultivation and commercial pillar, which up until this point had been in development. We can now realize the value of that investment heading into the second half of 2022 and into 2023. With the activation of this pillar, we are now one of only a handful of companies that are actively moving cannabis-derived products across the globe. We expect that flow of goods to increase substantially in the coming months as we continue to build relationships with regulatory agencies in the governments around the world,” commented Flora Growth CEO Luis Merchan. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC